The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 1, 2010, Pages 153-156

  Hasegawa, Yoshitaka ^a   Kishimoto, Shuichi ^a   Shibatani, Naoki ^a   Inotsume, Nobuo ^b   Takeuchi, Yoshikazu ^a   Fukushima, Shoji ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Diabetes; Disposition; Multidrug resistance associated protein 2; Organic anion transporting polypeptide 2; Pravastatin

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG TRANSPORT; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; LIVER CELL; MALE; NONHUMAN; PLASMA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; URINE;

ANIMALS; AREA UNDER CURVE; BILE; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; PRAVASTATIN; RATS; RATS, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 75149198686     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.153     Document Type: Article

References (13)

1. Shimojo N., Int. J. Biochem., 26, 1261-1268 (1994).
2. van Waarde W. M., Verkade H. J., Wolters H., Havinga R., Baller J., Bloks V., Muller M., Sauer P. J., Kuipers F., Gastroenterology, 122, 1842-1852 (2002).
3. Hatanaka T., Clin. Pharmacokinet., 39, 397-412 (2000).
4. Yamazaki M., Tokui T., Ishigami M., Sugiyama, Y., Biopharm. Drug Dispos., 17, 607-621 (1996).
5. Hatanaka T., Honda S., Sasaki S., Katayama K., Koizumi T., J. Pharmacokinet. Biopharm., 26, 329-347 (1998).
6. Komai T., Kawai K., Tokui T., Tokui Y., Kuroiwa C., Shigehara E., Tanaka M., Eur. J. Drug Metab. Pharmacokinet., 17, 103-113 (1992).
7. Muramatsu S., Miyaguchi K., Iwabuchi H., Matsushita Y., Nakamura T., Kinoshita T., Tanaka M., Takahagi H., Xenobiotica, 22, 487-498 (1992).
8. Shitara Y., Sugiyama Y., Pharmacol. Ther., 112, 71-105 (2006).
9. Yamazaki M., Akiyama S., Niimuma K., Nishigaki R., Sugiyama Y., Drug Metab. Dispos., 25, 1123-1129 (1997).
10. Kivistö K. T., Grisk O., Hofmann U., Meissner K., Möritz K. U., Ritter C., Arnold K. A., Lutjöohann D., von Bergmann K., Klöting I., Eichelbaum M., Kroemer H. K., Drug Metab. Dispos., 33, 1593-1596 (2005).
11. Stahl S., Davies M. R., Cook D. I., Graham M. J., Xenobiotica, 38, 725-777 (2008).
12. Kruh G. D., Belinsky M. G., Oncogene, 22, 7537-7552 (2003).
13. Mukherjee B., Mukherjee J. R., Chatterjee M., Immunol. Cell Biol., 72, 109-114 (1994).